You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

CIPROFLOXACIN Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Ciprofloxacin patents expire, and what generic alternatives are available?

Ciprofloxacin is a drug marketed by Chartwell, Baxter Hlthcare Corp, Bedford Labs, Dr Reddys, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira, Sentiss, Sun Pharm, Anchen Pharms, Ani Pharms, Dr Reddys Labs Ltd, Fosun Pharma, Rising, Altaire Pharms Inc, Amring Pharms, Fdc Ltd, Pai Holdings Pharm, Rubicon, Saptalis Pharms, Watson Labs Inc, Aiping Pharm Inc, Amneal, Aurobindo Pharma, Barr, Carlsbad, Hikma, Ivax Sub Teva Pharms, Mylan, Nostrum Labs, Pliva, Sun Pharm Inds Ltd, Taro, Teva, Unique, Watson Labs, Yiling, Baxter Hlthcare, Bedford, Inforlife, and Teva Pharms. and is included in fifty-two NDAs.

The generic ingredient in CIPROFLOXACIN is ciprofloxacin hydrochloride. There are thirty-four drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the ciprofloxacin hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ciprofloxacin

A generic version of CIPROFLOXACIN was approved as ciprofloxacin hydrochloride by RUBICON on June 9th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CIPROFLOXACIN?
  • What are the global sales for CIPROFLOXACIN?
  • What is Average Wholesale Price for CIPROFLOXACIN?
Drug patent expirations by year for CIPROFLOXACIN

See drug prices for CIPROFLOXACIN

Drug Sales Revenue Trends for CIPROFLOXACIN

See drug sales revenues for CIPROFLOXACIN

Recent Clinical Trials for CIPROFLOXACIN

Identify potential brand extensions & 505(b)(2) entrants

Shanghai Pulmonary Hospital, Shanghai, ChinaPhase 4
University of Missouri-ColumbiaPhase 4
SanofiPhase 1

See all CIPROFLOXACIN clinical trials

Pharmacology for CIPROFLOXACIN
Medical Subject Heading (MeSH) Categories for CIPROFLOXACIN
Paragraph IV (Patent) Challenges for CIPROFLOXACIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CIPRO Oral Suspension ciprofloxacin 250 mg/5 mL and 500 mg/ 5 mL 020780 1 2009-10-16

US Patents and Regulatory Information for CIPROFLOXACIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pliva CIPROFLOXACIN HYDROCHLORIDE ciprofloxacin hydrochloride TABLET;ORAL 076426-002 Jun 15, 2005 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare Corp CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 078024-001 Mar 18, 2008 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal CIPROFLOXACIN HYDROCHLORIDE ciprofloxacin hydrochloride TABLET;ORAL 075939-003 Jun 9, 2004 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.